本帖最后由 老马 于 2013-3-13 13:43 编辑
R) b0 {- Z6 d* I' u, Y* L" A$ G1 v9 \9 V6 ^/ S; n
健择（吉西他滨）+顺铂+阿瓦斯汀9 `9 M4 `0 E6 e! a+ X! B$ F
Gemzar +Cisplatin + Avastin
* {; k) A9 g7 V: qhttp://annonc.oxfordjournals.org/content/21/9/1804.full
6 v1 m4 d) B* f* d, d& d% Y( rOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) ' s' U: j% d) E x3 v
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. ' m1 `9 @) B4 k9 E$ a( S
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. : V3 l6 W7 D0 q
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 206)
4 p! K9 N4 `* b3 I+ g4 l& I
华为网盘附件：4 e' U* u: f& X0 {/ k# K
【华为网盘】ava.JPG6 o- X M2 B0 B5 R7 g; Z3 i) {: b( I
|
显身卡
